Studies have shown that, compared with nonbiologic disease-modifying antirheumatic drugs, TNF-α-blocking agents may contribute to the reduction of the risk of cardiovascular events in patients with rheumatoid arthritis [28, 29]. This evidence concerns the gene TNF and rheumatoid arthritis.